The octapeptide NAP has been shown to exert neuroprotective properties and reduce neuro-inflammatory responses. The aim of the present study was to investigate if NAP provides anti-inflammatory effects in acute murine colitis. To address this, C57BL/6 j mice were challenged with 3.5% dextran sulfate sodium from day 0 until day 6 to induce colitis, either treated intraperitoneally with NAP or placebo (NaCl 0.9%) from day 1 until day 6 post-induction (p.i.) and subjected to in depth macroscopic, microscopic and immunological evaluations. Whereas NAP application did not alleviate macroscopic (i.e. clinical) sequelae of colitis, lower numbers of apoptotic, but higher counts of proliferating/regenerating colonic epithelial cells could be observed in NAP as compared to placebo treated mice at day 7 p.i. Furthermore, lower numbers of adaptive immune cells such as T lymphocytes and regulatory T cells were abundant in the colonic mucosa and lamina propria upon NAP versus placebo treatment that were accompanied by less colonic secretion of pro-inflammatory mediators including IFN-γ and nitric oxide at day 7 p.i. In mesenteric lymph nodes, pro-inflammatory IFN-γ, TNF and IL-6 concentrations were increased in placebo, but not NAP treated mice at day 7 p.i., whereas interestingly, elevated anti-inflammatory IL-10 levels could be observed in NAP treated mice only. The assessed anti-inflammatory properties of NAP were not restricted to the intestinal tract, given that in extra-intestinal compartments such as the kidneys, IFN-γ levels increased in placebo, but not NAP treated mice upon colitis induction. NAP induced effects were accompanied by distinct changes in intestinal microbiota composition, given that colonic luminal loads of bifidobacteria, regarded as anti-inflammatory, "health-promoting" commensal species, were two orders of magnitude higher in NAP as compared to placebo treated mice and even naive controls. In conclusion, NAP alleviates intestinal and extra-intestinal pro-inflammatory sequelae of acute experimental colitis and may provide novel treatment options of intestinal inflammatory diseases in humans.
Introduction
The octapeptide NAP (namely NAPVSIPQ) was initially identified as the smallest neuroprotective fragment of the activity-dependent neuroprotective protein (ADNP) [1] . Human ADNP is highly expressed within the central nervous system (CNS) including microglia and astrocytes [2] and also in the spleen, peripheral blood leukocytes and macrophages [3] [4] [5] . The neuroprotective effects of NAP have been assessed in vitro and in multiple in vivo models of neuronal morbidities including Alzheimer's disease, stroke, closed head injury, fetal alcohol syndrome and neonatal hypoxia [1, [6] [7] [8] [9] [10] . The target of NAP activity was identified as microtubules [11] , through direct interaction with microtubule end binding proteins [12] , enlisting the microtubule associated protein tau to microtubules [13] , which in turn protects against apoptosis induced by oxidative stress [14] . Immunomodulatory and anti-oxidative actions have been proposed as potential underlying mechanisms for the beneficial effects exerted by NAP as in the case of multiple sclerosis [15] . Anti-inflammatory, protective effetcs of NAP have been shown in a mouse paradigm of closed head injury [16] , and in a model of brain injury associated with diabetes [17] . Excitotoxicity during brain development (modeling cerebral palsy) also benefited from NAP treatment, providing neuroprotection as well as protecting developing oligodendroglial cells [18] .
Inflammatory bowel diseases (IBD) are of multifactorial etiology and constitute chronic inflammatory conditions of the gastrointestinal tract (GIT) with acute episodes [19] [20] [21] . Whereas Crohn's disease may affect the entire GIT with the terminal ileum as predilection site ("ileitis terminalis"), ulcerative colitis is restricted to the large intestines [20, 21] . In a previous study, we were able to demonstrate that NAP application resulted in potent anti-inflammatory effects in acute murine small intestinal inflammation mimicking key features of Crohn's disease [22] . Remarkably, beneficial properties of NAP treatment were not restricted to the intestinal tract, given that extra-intestinal and even systemic collateral damages of inflammation could be ameliorated [23] . This prompted us in the present study for the first time to elucidate potential immune-modulatory effects of NAP in another acute intestinal inflammation model, but of different location, namely in acute murine colitis that was induced by the barrier-damaging agent dextran sulfate sodium (DSS) and mirrors key features of acute episodes of IBD such as ulcerative colitis [24, 25] .
Materials and methods

Ethics statement
All animal experiments were conducted in accordance with the local ethical committee (Tel Aviv University, Israel, registration number 01-16-016). Animal welfare was monitored twice daily by assessment of clinical conditions including body weight.
Mice, colitis induction and treatment
C57BL/6 j WT mice were obtained from Harlan (Envigo, Jerusalem, Israel). In order to avoid potential sex-related confounding effect [26] , only female mice were included in the study. For induction of acute colitis, three month old mice were treated with 3.5% (wt/vol) dextrane sulfate sodium (DSS; 40 kDa, MP Biomedicals, Illkirch, France) in drinking water (ad libitum) for 6 days. 24 h before necropsy, DSS was withdrawn and mice received regular tap water only as described previously [24, 26, 27] . The intake of DSS solution was controlled daily.
From day 3 until day 6 post-induction (p.i.), mice were either treated with synthetic NAP (1.0 mg per kg body weight; in NaCl 0.9%) or NaCl 0.9% (placebo, PLC) once daily via the intraperitoneal route. A potential antimicrobial effect of the NAP solution was excluded as described previously [28] . Naive mice (i.e. without colitis and without treatment; None) served as negative controls. Mice were kept in cages Fig. 1 . Macroscopic sequelae of NAP treatment in mice with acute colitis. In order to induce acute colitis, C57BL/6j wildtype mice were subjected to dextran sulfate sodium treatment from day 0 until day 6 post-induction (p.i.) as described in methods. Mice were treated either with synthetic NAP (open circles) or placebo (PLC; filled circles) from day 1 until day 6 p.i. Immediately before sacrifize at day 7 p.i., (A) clinical conditions were quantitated applying a standardized scoring system (see methods), (B) the relative loss of body weights between day 7 p.i. and day 0 determined (in%) and upon necropsy, (C) individual colonic lengths were measured (in cm). Means (black bars) and numbers of analyzed mice (in parentheses) are indicated. Data were pooled from three independent experiments. Fig. 2 . Microscopic sequelae of NAP treatment in mice with acute colitis. Upon induction of acute colitis by dextran sulfate sodium (from day 0 until day 6), mice were treated either with synthetic NAP (open circles) or placebo (PLC; filled circles) from day 1 until day 6 post-induction (p.i.). At necropsy (i.e. day 7 p.i.), (A) histopathological mucosal changes were quantitatively assessed in hematoxylin and eosin stained colonic paraffin sections applying a standardized histopathological scoring system (see methods). Furthermore, the average numbers of (B) apoptotic (positive for caspase-3, Casp3) and (C) proliferating colonic epithelial cells (positive for Ki67) from at least six high power fields (HPF, 400× magnification) per animal were determined microscopically in immunohistochemically stained colonic paraffin sections at day 7 p.i. Naive and untreated (None; open diamonds) mice served as negative controls. Means (black bars), level of significance (p-value) determined by Mann-Whitney U test and numbers of analyzed animals (in parentheses) are indicated. Data were pooled from three independent experiments.
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Peptides 101 (2018) [1] [2] [3] [4] [5] [6] [7] [8] [9] including filter tops within an experimental semi-barrier (accessible only with lab coat, overshoes, caps and sterile gloves) under standard conditions (22-24°C room temperature, 55 ± 15% humidity, 12 h light/12 dark cycle) and had free access to autoclaved standard chow (food pellets; Sniff, Soest, Germany) and tap water with or without DSS (ad libitum).
Clinical scoring
To assess clinical signs of colitis on a daily basis, a standardized cumulative clinical score (maximum 12 points), addressing the occurrence of blood in feces (0: no blood; 2: microscopic detection of blood by the Guajac method using Haemoccult, Beckman Coulter/PCD, Germany; 4: macroscopic blood visible), diarrhea (0: formed feces; 2: pasty feces; 4: liquid feces), and the clinical aspect (0: normal; 2: ruffled fur, less locomotion; 4: isolation, severely compromised locomotion, pre-final condition) was applied as described earlier [29] [30] [31] .
Sampling procedures
At day 7 p.i., mice were sacrificed by isofluran treatment (Abbott, Greifswald, Germany). Cardiac blood and tissue samples from mesenteric lymph nodes (MLN), kidney, and colon were removed under sterile conditions. Colonic lengths were determined with a ruler. Large intestinal samples from each mouse were collected in parallel for histopathological, immunohistochemical, microbiological, and immunological analyses.
Histopathology and immunohistochemistry
Immunohistopathological changes were determined in large intestinal ex vivo biopsies that had been immediately fixed in 5% formalin and embedded in paraffin. Sections (5 μm) were stained with hematoxylin and eosin (H&E), examined by light microscopy (100× magnification), and colonic histopathological changes quantitatively assessed applying an established histopathological scoring system (maximum 6 points; according to [32] ): Score 1 (mild mucosal 
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Peptides 101 (2018) [1] [2] [3] [4] [5] [6] [7] [8] [9] inflammatory cell infiltrates with intact epithelium); score 2 (inflammatory cell infiltrates into mucosa and submucosa with undamaged epithelium); score 3 (mucosal infiltrates with focal ulceration); score 4 (inflammatory cell infiltrates in mucosa and submucosa with focal ulceration); score 5 (moderate inflammatory cell infiltration into mucosa and submucosa with extensive ulceration); score 6 (transmural inflammation and extensive ulceration). The histopathological scores were assessed by an independent blinded investigator.
In situ immunohistochemical analysis of colonic paraffin sections was performed as reported earlier [29, [33] [34] [35] . Following antigen retrieval (except for B220 staining) in citrate buffer or (as in case of F4/ 80) in protease (0.05%, Sigma-Aldrich, Germany), primary antibodies against cleaved caspase-3 (Asp175, #9661, Cell Signaling, Leiden, Netherlands; 1:200), Ki67 (clone 16A8, #652401, BioLegend/Biozol, Eching, Germany; 1:200), F4/80 (clone BM8, #MF48015, Life Technologies, Carlsbad, Germany; 1:100), CD3 (#IR50361-2, Dako, Santa Clara, CA, USA; 1:5), FOXP3 (clone FJK-165, #14-5773, eBioscience, Frankfurt, Germany; 1:100) and B220 (#14-0452-81, eBioscience; 1:200) were used. After 30 min of incubation with the primary antibody, sections were incubated for another 30 min with the respective secondary antibody (for anti-CD3 and anti-caspase-3 staining: biotinylated donkey anti-rabbit antibody; for anti-FOXP3: biotinylated donkey anti-rat antibody; for anti-F4/80 and anti-B220: biotinylated rabbit anti-rat antibody; all from Dianova, Hamburg, Germany). The Streptavidin-Alkaline Phosphatase Kit (Dako) using Fast Red as chromogen was applied as detection system. Negative controls were generated in samples in which the respective primary antibody had been omitted. Images were taken with an Axiolmager Z1 microscope and subsequently processed with the Axiovision software (Carl Zeiss MicroImaging, Jena, Germany). For each animal, the average number of positively stained cells within at least six high power fields (HPF, 0.287 mm 2 , 400× magnification) were determined microscopically by an independent blinded investigator.
Cytokine measurements
Colonic samples were cut longitudinally and washed in phosphate buffered saline (PBS; Gibco, life technologies, Paisley, UK). Ex vivo biopsies derived from kidney (one half after longitudinal cut) or strips of approximately 1 cm 2 colonic tissue were placed in 24-flat-bottom well culture plates (Nunc, Wiesbaden, Germany) containing 500 μl serum-free RPMI 1640 medium (Gibco, life technologies) supplemented with penicillin (100 U/ mL) and streptomycin (100 μg/ mL; PAA Laboratories). After 18 h at 37°C, culture supernatants and serum samples were tested for IFN-γ, TNF, IL-6, MCP-1, and IL-10 by the Mouse Inflammation Cytometric Bead Assay (CBA; BD Biosciences, Heidelberg, Germany) on a BD FACSCanto II flow cytometer (BD Biosciences) as described earlier [23, 33, 36] . Nitric oxide (NO) concentrations were determined by the Griess reaction as stated elsewhere [37, 38] . In brief, 50 μl of culture supernatant were mixed with 50 μl of 1.5% sulfanilamide (Roth, Germany) in 1 M HCl plus 0.15% N-(1-naphthyl)ethylenediamine dihydrochloride (Sigma-Aldrich, Germany). After 10 min the absorbance was measured photometrically at 540 nm and nitrite concentrations were calculated from standard curves.
Molecular analysis of fecal microbiota
Fresh colonic luminal samples were immediately snap-frozen in liquid nitrogen and stored at −80°C until further processing. DNA was extracted from colonic luminal samples as described earlier [37, 39] . In brief, DNA was quantified by using Quant-iT PicoGreen reagent (Invitrogen, UK) and adjusted to 1 ng per μl. Then, the main bacterial groups abundant in the murine intestinal microbiota including enterobacteria, enterococci, lactobacilli, bifidobacteria, Bacteroides/Prevotella spp., Clostridium coccoides group, Clostridium leptum group as well as total eubacterial loads were assessed by quantitative real-time polymerase chain reaction (qRT-PCR) with species-, genera-or groupspecific 16S rRNA gene primers (Tib MolBiol, Germany) as reported previously [33, [40] [41] [42] [43] , and numbers of 16S rRNA gene copies per ng DNA of each sample were determined.
Statistical analysis
Medians and levels of significance were determined using MannWhitney test (GraphPad Prism v5, La Jolla, CA, USA) as indicated. Twosided probability (p) values ≤ 0.05 were considered significant.
Results
Macroscopic sequelae of NAP treatment in mice suffering from acute colitis
In order to address potential anti-inflammatory properties of NAP in experimental colitis, conventional wildtype mice were subjected to DSS for six days and either intraperitoneally treated with synthetic NAP or placebo from day 1 until day 6 p.i. Immediately before necropsy at day 7 following colitis induction, mice exhibited comparable macroscopic signs of colitis irrespective of the treatment regimen as indicated by similar clinical scores, weight losses and colonic lengths (n.s.; Fig. 1 ). Hence, NAP did not alleviate clinical signs of acute DSS colitis.
Microscopic sequelae of NAP treatment in mice suffering from acute colitis
We next investigated microscopic changes in colonic ex vivo biopsies derived from NAP treated mice. At day 7 p.i., both NAP and placebo treated mice displayed overt signs of acute colitis (p < 0.001 vs naive controls; Fig. 2 ) such as mucosal and submucosal inflammatory infiltrates, ulcerations and granulocyte fibrin eschar (Fig. S1 ), but of similar severity as indicated by comparable histopathological scores (n.s.; Fig. 2 ). Since apoptosis is regarded a valuable diagnostic marker in the histopathological evaluation and grading of intestinal disease [33] , we further quantitatively assessed numbers of caspase-3+ cells within the colonic mucosa. Apoptotic colonic epithelial cell numbers increased upon colitis development (p < 0.001; Fig. 2B ), whereas this increase was less pronounced in NAP treated mice (p < 0.005; Fig. 2B ). Given that Ki67 comprizes a nuclear protein associated with and necessary for cellular proliferation [44] , we also stained colonic paraffin sections against Ki67 in order to determine potential proliferative/regenerative measures of the colonic epithelium counter-acting DSS induced apoptosis. Interestingly, both NAP and placebo treated mice displayed increased Ki67+ cell numbers in their colonic mucosa at day 7 p.i. as compared to naive mice (p < 0.001; Fig. 2C ). This increase, however, was much more pronounced following NAP as compared to placebo treatment (p < 0.005; Fig. 2C ). Hence, NAP treatment of mice suffering from acute DSS colitis ameliorates colonic epithelial apoptosis and accelerates cell regenerative responses.
Colonic immune responses upon NAP treatment of mice suffering from acute colitis
We next quantitatively assessed the abundances of distinct innate and adaptive immune cell populations within the colonic mucosa and lamina propria upon colitis induction and NAP treatment applying in situ immunohistochemistry. Whereas until day 7 p.i. the numbers of large intestinal macrophages and monocytes as well as of B lymphocytes had multifold increased in both NAP and placebo treated mice (p < 0.001 vs naive; Fig. 3A, D) , colitis-induced augmentations in T lymphocytes and regulatory T cells were less pronounced following NAP as compared to placebo treatment (p < 0.05 and p < 0.001, respectively; Fig. 3C, D) . This was accompanied by lower colonic levels of pro-inflammatory mediators such as IFN-γ and nitric oxide in mice which had been subjected to NAP versus placebo (p < 0.05; Fig. 4) . We further assessed cytokine secretion in MLN. Interestingly, only in placebo treated mice increased concentrations of pro-inflammatory cytokines such as IFN-γ, TNF and IL-6 could be measured in MLN at day 7 p.i. (p < 0.05 vs naive; Fig. 5A-C) . Conversely, NAP treatment resulted in increased anti-inflammatory IL-10 levels in MLN (p < 0.05 vs naive; Fig. 5D ). Hence, NAP exerts anti-inflammatory properties in the intestinal tract of mice suffering from acute DSS colitis.
Extra-intestinal and systemic pro-inflammatory cytokine responses upon NAP treatment of mice suffering from acute colitis
We further addressed whether the anti-inflammatory properties exerted by NAP were restricted to the intestinal tract or could also be observed in extra-intestinal including systemic compartments. At day 7 
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Peptides 101 (2018) 1-9 p.i., IFN-γ secretion was enhanced in kidneys of placebo, but not of NAP treated mice (p < 0.001 vs naive; Fig. 6 ). NAP application was, however, not sufficient to alleviate systemic pro-inflammatory responses upon colitis induction as indicated by comparably augmented pro-inflammatory cytokines including IFN-γ, TNF, MCP-1 and IL-6 in serum samples taken at day 7 p.i. (p < 0.005-0.001; Fig. S2A-D) . Serum concentrations of anti-inflammatory IL-10 were, however, virtually completely suppressed in mice with acute colitis irrespective of the treatment regimen (p < 0.005-0.001 vs naive; Fig. S2E ). Hence, NAP is capable or exerting anti-inflammatory effects also in extra-intestinal compartments such as the kidneys.
Large intestinal microbiota changes upon NAP treatment of mice suffering from acute colitis
Given the deep impact of the commensal gut microbiota in health and disease [37, 43, [45] [46] [47] [48] [49] , we next performed a comprehensive comparative survey of the complex large intestinal microbiota composition in NAP versus placebo treated mice suffering from acute colitis. At day 7 p.i., higher loads of commensal enterobacteria, Clostridium coccoides and Clostridium leptum could be observed in the colonic lumen of both NAP and placebo treated mice as compared to naive controls (p < 0.05-0.001; Fig. 7B , G, H), whereas total eubacterial and enterococcal gene numbers remained virtually unchanged (n.s.; Fig. 7A , C). Obligate anerobic gram-negative species such as Bacteroides/Prevotella, however, had increased in the large intestines of NAP treated mice until day 7 p.i. (p < 0.05; Fig. 7F ), while colonic luminal gene numbers of lactobacilli were lower in placebo-animals as compared to NAP treated mice at day 7 p.i. as well as to naive controls (p < 0.001 and p < 0.05, respectively; Fig. 7D ). Remarkably, colonic loads of bifidobacteria (regarded as potentially anti-inflammatory, health-promoting, probiotic bacterial species) were highest in the NAP cohort and even up to 3 orders of magnitude higher as compared to naive control mice (p < 0.001; Fig. 7E ). Hence, acute colitis induction is accompanied with distinct gut microbiota shifts, whereas NAP treated mice with colitis harbor increased bifidobacterial loads in their colon.
Discussion
In the present study we investigated for the first time potential beneficial effects of NAP in an acute large intestinal inflammation model. We were able to demonstrate that NAP exerted potent anti-inflammatory effects in acute DSS induced colitis of mice as indicated by i.) less colonic apoptosis, but increased mucosal cell proliferation and regeneration, ii.) less influx of adaptive immune cell subsets into the colonic mucosa and lamina propria, and iii.) less secretion of pro-inflammatory mediators in the colon, MLN and even extra-intestinal compartments such as the kidney. Furthermore, iv.) NAP treated mice harbored increased loads of potentially "health-promoting" and antiinflammatory commensal species such as bifidobacteria.
Whereas clinical symptoms of acute colitis could not be alleviated, NAP treated mice were suffering from less distinct large intestinal apoptosis, as indicated by lower numbers of caspase-3 positive cells within the colonic epithelia. In our previous study applying another acute intestinal inflammation model, but at different location, namely the small intestinal tract, NAP application resulted in less abundance of caspase-3 positive cells in ileal epithelia [23] . Our data are well in line with recent studies demonstrating that the cell survival promoting activity of NAP in the CNS was due to prevention of caspase-3 activation and, thus, of apoptotic cell death [14, 50] . Conversely, numbers of Ki67 positive cells within the colonic as well as the ileal mucosa were increased upon NAP treatment, indicative for proliferative measures of the large and small intestinal epithelia thereby counteracting apoptotic cell damage as shown here and in our previous report [23] .
NAP treatment of mice suffering from acute colitis was further accompanied by lower numbers of adaptive immune cells such as T lymphocytes within the colonic mucosa and lamina propria. This also held true for acute murine ileitis as shown by us previously, given that NAP treatment resulted in dampened Th1-type immune responses as indicated by reduced influx of T lymphocytes, the major driving forces of Toxoplasma gondii induced ileitis [22] , into the small intestinal tract [22, 23] . In support, Braitch and colleagues showed that T lymphocytes derived from peripheral blood mononuclear cells of healthy blood donors expressed ADNP, whereas NAP application in vitro suppressed proliferation as well as activation of T lymphocytes resulting in decreased secretion of pro-inflammatory cytokines including IFN-γ [15] . In our present study, not only colonic concentration of IFN-γ, but also of nitric oxide exerting oxidative stress to the colonic epithelium were reduced following NAP treatment. In MLN of NAP, but not placebo treated mice, IFN-γ, TNF and IL-6 concentrations were comparable to those measured in naive controls, whereas anti-inflammatory IL-10 concentrations were increased, further supporting the anti-inflammatory properties of NAP in the intestinal tract, both in murine colitis and ileitis [23] . This is well in line with in vitro data showing that NAP suppressed the production TNF and IL-6 from murine macrophages [5] and of TNF in vivo immediately following head trauma [6] .
Clinical evidence suggests that also extra-intestinal organs might be affected in IBD patients [51, 52] . Interestingly, a recent murine study revealed that acute DSS colitis was accompanied by inflammatory responses in the kidneys [53] . Remarkably, the beneficial effects of NAP observed in our present study were not restricted to the intestines, but could also be observed in extra-intestinal compartments, given that renal IFN-γ levels were not increased in NAP treated mice with acute colitis and comparable to naive mice.
Since the distinct intestinal microbiota composition is well known to play a critical role in the initiation and perpetuation of immunopathological conditions [24, 29, 37, 40, 48, 49, [54] [55] [56] , we additionally performed a comprehensive survey of the gut microbiota composition and of potential shifts therein during colitis and NAP treatment. Of note, we had initially ruled out that NAP exerted any antibacterial effects in vitro [23] . In line with previous reports, potentially pro-inflammatory commensals such as enterobacteria (i.e. Escherichia coli) and Bacteroides/Prevotella species increased upon colitis development [24, 57] . Furthermore, intestinal microbiota shifts (dysbiosis) with decreased bifidobacterial loads have been shown to be associated with human intestinal morbidities such as IBD, celiac disease and atopic disease [58] . As reported by us previously, mice that were gene deficient for Toll-like receptor (TLR) −9 or nucleotide-binding oligomerization domain (NOD) −2 were deprived from intestinal bifidobacteria under conventional housing conditions, but developed more severe disease upon acute ileitis induction [39, 59] . In our present study, much higher colonic luminal loads of bifidobacteria could be observed in NAP treated as compared to placebo treated mice and even to naive controls. Bifidobacteria belonging to the phylum Actinobacteria are regarded as anti-inflammatory, probiotic, "health-promoting" commensal species for many reasons as unraveled by genome-based analyses [60] . Besides several metabolic properties including production of vitamins and fatty acids, hydrolysis of bile salts and degradation of oxalate [60] , a very recent report provided a direct link between bifidobacteria and neuromodulatory activities, given that a particular Bifidobacterium dentium strain was able to modulate visceral sensitivity in the intestinal tract by production of γ-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the CNS of mammals [61] . This report together with our study further underlines the (patho)physiological importance of the gut-brain-axis.
It is tempting to speculate that the observed beneficial sequelae of NAP treatment might have been even more pronounced upon increases in dosage and/or application frequencies of NAP (e.g. twice instead of only once daily) or following prophylactic application starting before colitis induction. In addition, NAP induced effects might be more pronounced in a less acute, thus more chronic inflammation model, which needs to be addressed in future studies.
In summary, we show here for the first time that the peptide NAP exerts potent intestinal and extra-intestinal anti-inflammatory properties during acute experimental colitis. NAP (davunetide, CP201), previously showing efficacy in phase II clinical trials including amnestic mild cognitive impairment and schizophrenia (cognitive scores and functional activity, respectively), is now planned for clinical studies in the autism-related ADNP syndrome by Coronis Neurosciences [62] .
We conclude that these findings provide novel treatment options of intestinal inflammatory diseases including IBD such as ulcerative colitis and Crohn's disease.
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